About the Authors

Aislyn D. W. Boran

Affiliation Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America

Joseph Seco

Affiliation Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America

Vinodh Jayaraman

Affiliation Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America

Gomathi Jayaraman

Affiliation Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America

Shan Zhao

Affiliation Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America

Sushmitha Reddy

Affiliation Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America

Yibang Chen

Affiliation Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America

Ravi Iyengar

ravi.iyengar@mssm.edu

Affiliation Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America

Competing Interests

The authors have read the journal’s policy and have the following conflicts: U.S. Patent Application: AB, YC and RI “Cell-permeable peptides as receptor tyrosine kinase antagonists.” U.S. Patent Application no. 61/107,650. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: AB YC RI. Performed the experiments: AB JS VJ GJ SR YC. Analyzed the data: AB JS VG SZ. Wrote the paper: AB RI.